Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan;12(1):56-61.
doi: 10.1038/nrneurol.2015.177. Epub 2015 Sep 29.

CAP--advancing the evaluation of preclinical Alzheimer disease treatments

Eric M Reiman  1 , Jessica B Langbaum  1 , Pierre N Tariot  1 , Francisco Lopera  2 , Randall J Bateman  3 , John C Morris  3 , Reisa A Sperling  4 , Paul S Aisen  5 , Allen D Roses  6 , Kathleen A Welsh-Bohmer  6 , Maria C Carrillo  7 , Stacie Weninger  8
Affiliations
Review

CAP--advancing the evaluation of preclinical Alzheimer disease treatments

Eric M Reiman et al. Nat Rev Neurol. 2016 Jan.

Abstract

If we are to find treatments to postpone, reduce the risk of, or completely prevent the clinical onset of Alzheimer disease (AD), we need faster methods to evaluate promising preclinical AD treatments, new ways to work together in support of common goals, and a determination to expedite the initiation and performance of preclinical AD trials. In this article, we note some of the current challenges, opportunities and emerging strategies in preclinical AD treatment. We describe the Collaboration for Alzheimer's Prevention (CAP)-a convening, harmonizing and consensus-building initiative to help stakeholders advance AD prevention research with rigour, care and maximal impact-and we demonstrate the impact of CAP on the goals and design of new preclinical AD trials.

PubMed Disclaimer

Conflict of interest statement

Competing interests

All authors except M.C.C. declare competing interests. See the article online for full details of the relationships.

References

    1. Alzheimer’s Association. 2013 Alzheimer’s Disease Facts and Figures. Alzheimers Dement. 2013;9:208–245. - PubMed
    1. Sperling RA, Jack CR, Jr, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med. 2011;3:111cm33. - PMC - PubMed
    1. Reiman EM, Langbaum JB. Brain imaging in the evaluation of putative Alzheimer’s disease slowing, risk-reducing and prevention therapies. In: Jagust WJ, D’Esposito M, editors. Imaging the Aging Brain. Oxford University Press; 2009. pp. 319–350.
    1. Bateman RJ, et al. Autosomal-dominant Alzheimer’s disease: a review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res Ther. 2011;3:1. - PMC - PubMed
    1. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337–1342. - PMC - PubMed

Publication types

MeSH terms

Substances